These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Effector mechanisms of PNS demyelination in Gal-C induced-EAN]. Saida K Rinsho Shinkeigaku; 1990 Dec; 30(12):1361-3. PubMed ID: 2129197 [TBL] [Abstract][Full Text] [Related]
3. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Dalakas MC Pharmacol Ther; 2004 Jun; 102(3):177-93. PubMed ID: 15246245 [TBL] [Abstract][Full Text] [Related]
6. Inflammatory mediators in demyelinating disorders of the CNS and PNS. Hartung HP; Jung S; Stoll G; Zielasek J; Schmidt B; Archelos JJ; Toyka KV J Neuroimmunol; 1992 Oct; 40(2-3):197-210. PubMed ID: 1331168 [TBL] [Abstract][Full Text] [Related]
7. Recent advances in the understanding of the immunological basis of peripheral neuropathies. Larner AJ Br J Clin Pract; 1993; 47(5):262-5. PubMed ID: 8292474 [TBL] [Abstract][Full Text] [Related]
8. Experimental allergic neuritis (EAN) as a model for the immune-mediated demyelinating neuropathies. Hahn AF Rev Neurol (Paris); 1996 May; 152(5):328-32. PubMed ID: 8881424 [TBL] [Abstract][Full Text] [Related]
9. Effector mechanisms in anti-MAG antibody-mediated and other demyelinating neuropathies. Latov N; Renaud S J Neurol Sci; 2004 May; 220(1-2):127-9. PubMed ID: 15140620 [No Abstract] [Full Text] [Related]
19. [The role of complement in autoimmune thyroid disorders]. Potluková E; Limanová Z Cas Lek Cesk; 2007; 146(3):210-4. PubMed ID: 17419301 [TBL] [Abstract][Full Text] [Related]
20. Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies. Zhang G; Lopez PH; Li CY; Mehta NR; Griffin JW; Schnaar RL; Sheikh KA Brain; 2004 May; 127(Pt 5):1085-100. PubMed ID: 14985267 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]